keyword
MENU ▼
Read by QxMD icon Read
search

tenecteplase

keyword
https://www.readbyqxmd.com/read/27904506/safety-and-efficacy-of-tenecteplase-versus-alteplase-in-acute-coronary-syndrome-a-systematic-review-and-meta-analysis-of-randomized-trials
#1
REVIEW
Alexandre Guillermin, David Jun Yan, Arnaud Perrier, Christophe Marti
INTRODUCTION: Alteplase and tenecteplase are two widely used thrombolytic agents and are both approved for the treatment of acute myocardial infarction. These two molecules have increased fibrin specificity compared with older thrombolytics but distinct pharmacokinetic properties and may differ in terms of risks and benefits. We decided to review the available evidence comparing the safety and efficacy of these two molecules in acute coronary syndrome (ACS) or pulmonary embolism (PE)...
December 1, 2016: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/27831633/therapeutic-effect-of-tenecteplase-on-treatment-of-cerebral-arterial-thrombosis-a-meta-analysis
#2
Y Zang, J Hou, L-Y Wang
OBJECTIVE: To evaluate the clinical efficacy between tenecteplase (TNK) and alteplase (rt-PA). Furthermore, suitable dosage of TNK in cerebral arterial thrombosis treatment was explored. MATERIALS AND METHODS: The studies met with the predefined selection criteria were selected for the present study. The quality of each study was evaluated by Cochrane quality evaluation. The outcome indexes including early major neurological improvement (MNI), excellent recovery, good recovery, recanalization at 24 hours-complete or partial, symptomatic intracranial hemorrhage, any parenchymal hematoma and deaths were analyzed by using RevMan and Stata statistical software, under a random-effects model or a fixed-effects model...
October 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27739276/successful-thrombolysis-of-a-large-pulmonary-artery-thrombosis
#3
Ajay U Mahajan, Deepak S Laddhad, Deepak Bohara, Sangeeta D Laddhad, Yogita T Dinde, Sachin S Bhabad
A 32 yrs old man presented with shortness of breath and syncopal episode with preceding history of DVT 15days above. Patient has tachycardia hypoxia and hypotension, on evaluation ECG Showed S1 Q3 T3 Pattern, bedside Echo Showed visible thrombus of 3cm in pulmonary artery, successfully thrombolysed with tenecteplase and streptokinase. This case study is presented to stress importance of urgent bedside echo in all sudden onset dysponea and hypoxia to rule out pulmonary Embolism which can be successfully thrombolysed without delay...
June 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27729670/alteplase-and-tenecteplase-confusion-lack-of-e-prescribing-interoperability-leads-to-double-dosing-accidental-overdoses-involving-fluorouracil-infusions
#4
EDITORIAL
Michael R Cohen, Judy L Smetzer
These medication errors have occurred in health care facilities at least once. They will happen again-perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them at your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the Institute for Safe Medication Practices (ISMP) Medication Errors Reporting Program...
November 2015: Hospital Pharmacy
https://www.readbyqxmd.com/read/27621501/fda-advise-err-mefloquine-not-the-same-as-malarone-zoster-vaccine-is-not-for-the-immunosuppressed-txa-mistaken-as-tenecteplase-guidelines-for-adult-iv-push-medications
#5
EDITORIAL
Michael R Cohen, Judy L Smetzer
These medication errors have occurred in health care facilities at least once. They will happen again-perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them at your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the Institute for Safe Medication Practices (ISMP) Medication Errors Reporting Program...
November 2015: Hospital Pharmacy
https://www.readbyqxmd.com/read/27599905/the-enhancing-effect-of-focused-ultrasound-on-tnk-tissue-plasminogen-activator-induced-thrombolysis-using-an-in-vitro-circulating-flow-model
#6
Nicos Papadopoulos, Christos Yiallouras, Christakis Damianou
BACKGROUND: The limited efficacy of thrombolytic therapy in patients with ischemic stroke has created the need to use focused ultrasound (FUS) energy as a way to enhance thrombolysis efficacy (sonothrombolysis). Using an in vitro circulating flow model, we evaluated the role of physical parameters on tenecteplase (TNK-tPA)-mediated thrombolysis. MATERIALS AND METHODS: Fully retracted porcine blood clots were used for the proposed experimental study. To provide a more realistic clinical environment of stroke, the study was conducted under realistic flow conditions and TNK-tPA concentrations...
September 2, 2016: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/27472425/thrombolysis-and-thrombectomy-for-acute-ischemic-stroke-strengths-and-synergies
#7
Bruce C V Campbell
Acute ischemic stroke is responsible for around 80% of all strokes and is a leading cause of disability and death globally. There are two potential treatment strategies: restoring blood flow (reperfusion) and preventing cellular injury (neuroprotection). As yet, all the successful trials have involved reperfusion with numerous failures of neuroprotectants. There are two proven reperfusion strategies. Intravenous thrombolysis with alteplase was first demonstrated to reduce disability with publication of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator trial in 1995...
July 29, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27247518/management-of-acute-submacular-hemorrhage-with-intravitreal-injection-of-tenecteplase-anti-vascular-endothelial-growth-factor-and-gas
#8
Jung Pil Lee, Jun Sang Park, Oh Woong Kwon, Yong Sung You, Soon Hyun Kim
PURPOSE: To evaluate the visual and anatomical outcomes for neovascular age-related macular degeneration with submacular hemorrhage after intravitreal injections of tenecteplase (TNK), anti-vascular endothelial growth factor (VEGF) and expansile gas. METHODS: This study was a retrospective clinical case series following 25 eyes of 25 patients. All patients received a triple injection using 0.05 mL TNK (50 µg), 0.05 mL anti-VEGF and 0.3 mL of perfluoropropane gas...
June 2016: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/27156900/in-vitro-evaluation-of-focused-ultrasound-enhanced-tnk-tissue-plasminogen-activator-mediated-thrombolysis
#9
Nikolaos Papadopoulos, Christakis Damianou
INTRODUCTION: The low and incomplete recanalization performance of thrombolytic therapy in patients with acute ischemic stroke has created the need to use focused ultrasound (FUS) energy as a way to enhance thrombolysis efficiency (sonothrombolysis). Using an in vitro flow model, the role of various parameters involved in FUS-enhanced tenecteplase (TNK-tPA [tissue plasminogen activator])-mediated thrombolysis was evaluated. MATERIALS AND METHODS: Fully retracted porcine blood clots were used for the proposed parametric studies...
August 2016: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/27133326/two-year-follow-up-data-from-the-stepp-ami-study-a-prospective-observational-multicenter-study-comparing-tenecteplase-facilitated-pci-versus-primary-pci-in-indian-patients-with-stemi
#10
Suma M Victor, S Vijayakumar, Thomas Alexander, C G Bahuleyan, Arun Srinivas, S Selvamani, S Marutha Priya, K Kamaleswari, Ajit S Mullasari
BACKGROUND: A pharmacoinvasive strategy may alleviate the logistical and geographical barriers in timely reperfusion of ST-segment elevation myocardial infarction (STEMI), especially in a developing country like India. AIM: To assess the safety and efficacy of pharmacoinvasive strategy versus primary PCI in STEMI patients at 2 years. METHODS: Patients enrolled in STEPP-AMI, an observational, multicenter, prospective study of 200 patients presenting with STEMI, were followed up for 2 years...
March 2016: Indian Heart Journal
https://www.readbyqxmd.com/read/27048693/tenecteplase-versus-alteplase-in-stroke-thrombolysis-an-individual-patient-data-meta-analysis-of-randomized-controlled-trials
#11
Xuya Huang, Rachael MacIsaac, John Lp Thompson, Bruce Levin, Richard Buchsbaum, E Clarke Haley, Christopher Levi, Bruce Campbell, Christopher Bladin, Mark Parsons, Keith W Muir
BACKGROUND: Tenecteplase, a modified plasminogen activator with higher fibrin specificity and longer half-life, may have advantages over alteplase in acute ischemic stroke thrombolysis. AIMS: We undertook an individual patient data meta-analysis of randomized controlled trials that compared alteplase with tenecteplase in acute stroke. METHODS: Eligible studies were identified by a MEDLINE search, and individual patient data were acquired. We compared clinical outcomes including modified Rankin Scale at three months, early neurological improvement at 24 h, intracerebral hemorrhage, symptomatic intracerebral hemorrhage, and mortality at three months between all dose tiers of tenecteplase and alteplase...
July 2016: International Journal of Stroke: Official Journal of the International Stroke Society
https://www.readbyqxmd.com/read/26993894/midterm-results-of-percutaneous-endovascular-treatment-for-acute-and-chronic-deep-venous-thrombosis
#12
Gregory A Stanley, Erin H Murphy, Mitchell M Plummer, Jayer Chung, J Gregory Modrall, Frank R Arko
BACKGROUND: Treatment of deep venous thrombosis (DVT) with therapeutic anticoagulation has been increasingly challenged by aggressive percutaneous treatment using ultrasound-accelerated catheter-directed thrombolysis (US-CDT) or percutaneous pharmacomechanical thrombectomy (PMT). These techniques have been promoted to improve thrombus removal, prolong venous patency, prevent venous insufficiency, and reduce postthrombotic syndrome. This study reviews midterm results using these endovascular techniques for both acute and chronic DVT...
January 2013: Journal of Vascular Surgery. Venous and Lymphatic Disorders
https://www.readbyqxmd.com/read/26933345/feasibility-and-efficacy-of-thrombolysis-in-acute-ischemic-stroke-a-study-from-national-institute-of-neurological-and-allied-sciences-kathmandu-nepal
#13
Lekhjung Thapa, Shikher Shrestha, Pratyush Shrestha, Suman Bhattarai, D N Gongal, U P Devkota
BACKGROUND: Stroke is the major cause of morbidity and mortality worldwide. The number of stroke patients receiving recombinant tissue plasminogen activator (rt-PA), also known as Alteplase, in the developing world is extremely low. We aim to study the feasibility and efficacy of thrombolysis for the 1(st) time in our country. MATERIALS AND METHODS: In this retrospective study (July 2012-August 2015), acute ischemic stroke patients who were thrombolyzed within 3 h of stroke onset were included...
January 2016: Journal of Neurosciences in Rural Practice
https://www.readbyqxmd.com/read/26909366/structural-basis-of-specific-inhibition-of-tissue-type-plasminogen-activator-by-plasminogen-activators-inhibitor-1
#14
Lihu Gong, Min Liu, Tu Zeng, Xiaoli Shi, Cai Yuan, Peter A Andreasen, Mingdong Huang
Thrombosis is a leading cause of death worldwide [1]. Recombinant tissue-type plasminogen activator (tPA) is the FDA-approved thrombolytic drug for ischemic strokes, myocardial infarction and pulmonary embolism. tPA is a multi-domain serine protease of the trypsin-family [2] and catalyses the critical step in fibrinolysis [3], converting the zymogen plasminogen to the active serine protease plasmin, which degrades the fibrin network of thrombi and blood clots. tPA is rapidly inactivated by endogenous plasminogen activators inhibitor-1 (PAI-1) [4] (Fig...
March 2016: Data in Brief
https://www.readbyqxmd.com/read/26866684/variable-resistance-to-plasminogen-activator-initiated-fibrinolysis-for-intermediate-risk-pulmonary-embolism
#15
RANDOMIZED CONTROLLED TRIAL
William B Stubblefield, Nathan J Alves, Matthew T Rondina, Jeffrey A Kline
BACKGROUND: We examine the clinical significance and biomarkers of tissue plasminogen activator (tPA)-catalyzed clot lysis time (CLT) in patients with intermediate-risk pulmonary embolism (PE). METHODS: Platelet-poor, citrated plasma was obtained from patients with PE. Healthy age- and sex-matched patients served as disease-negative controls. Fibrinogen, α2-antiplasmin, plasminogen, thrombin activatable fibrinolysis inhibitor (TAFI), plasminogen activator Inhibitor 1 (PAI-1), thrombin time and D-dimer were quantified...
2016: PloS One
https://www.readbyqxmd.com/read/26849132/drug-treatment-of-stemi-in-the-elderly-focus-on-fibrinolytic-therapy-and-insights-from-the-stream-trial
#16
REVIEW
Peter R Sinnaeve, Thierry Danays, Kris Bogaerts, Frans Van de Werf, Paul W Armstrong
Elderly patients constitute a large and growing proportion of ST-elevation myocardial infarction (STEMI) patients, yet they have been under-represented or even excluded from reperfusion trials. Despite evidence that fibrinolysis improves outcomes irrespective of age, many elderly STEMI patients still remain undertreated or subject to major delays to primary percutaneous coronary intervention (PCI). The fear of an excessive risk of intracranial hemorrhage (ICH) in these patients can lead to avoidance of potentially life-saving reperfusion treatment, despite the fact that current STEMI guidelines do not exclude the elderly from a pharmaco-invasive strategy...
February 2016: Drugs & Aging
https://www.readbyqxmd.com/read/26798040/novel-thrombolytics-for-acute-ischemic-stroke-challenges-and-opportunities
#17
Nicola Logallo, Christopher E Kvistad, Aliona Nacu, Lars Thomassen
Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in ischemic stroke patients have shown neutral results and a promising safety profile, but the trials compared desmoteplase with placebo only in late admitted patients. Future trials should focus on testing novel thrombolytics in the early time window either as the sole acute recanalizing treatment or combined with thrombectomy...
February 2016: CNS Drugs
https://www.readbyqxmd.com/read/26688154/successful-use-of-tenecteplase-in-a-patient-with-recurrence-of-prosthetic-mitral-valve-thrombosis
#18
Harshal A Lahoti, Bal Krishna Goyal
INTRODUCTION: Tenecteplase can be a more effective and convenient alternative in treatment of prosthetic valve thrombosis (PVT). CASE: We hereby present a case of the use of Tenecteplase for recurrence of mitral valve thrombosis in a patient who was brought as an emergency with breathing difficulty at rest. A single intravenous bolus of Tenecteplase relieved her symptoms dramatically within a few hours. This is in contradistinction to her earlier similar presentation with valve thrombosis a year back, when both streptokinase and urokinase had not worked...
December 2015: Indian Heart Journal
https://www.readbyqxmd.com/read/26563662/-intravenous-thrombolysis-in-ischemic-stroke-therapeutic-perspectives
#19
REVIEW
C Paris, L Derex
New therapeutic strategies are under evaluation to improve the treatment of acute ischemic stroke (AIS). Approaches combining intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) and antithrombotic agents are currently evaluated. The combination of IV rt-PA and aspirin showed a high rate of intracranial hemorrhage whereas the association of rt-PA and eptifibatide seems more promising. The results of recent studies evaluating the administration of eptifibatide or argatroban in conjunction with conventional IV thrombolysis with rt-PA are expected to clarify the safety and efficacy of these treatments...
December 2015: Revue Neurologique
https://www.readbyqxmd.com/read/26534418/budget-impact-analysis-of-the-use-of-tenecteplase-in-the-treatment-of-acute-myocardial-infarction-in-mexico
#20
J L Huicochea-Bartelt, E Palacios, L Zapata, S Herran
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
115345
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"